Xeris Biopharma Holdings Inc. diskutieren
Xeris Biopharma Holdings Inc.
WKN: A3C4ZC / Symbol: XERS / Name: Xeris Biopharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
4,58 €
3,19 %
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $4.50 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target lowered by analysts at Piper Sandler from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at HC Wainwright from $6.00 to $6.60. They now have a "buy" rating on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $6.00 price target on the stock, up previously from $4.00.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock, up previously from $6.60.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at Craig Hallum from $5.00 to $6.50. They now have a "buy" rating on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at Leerink Partners from $5.00 to $6.00. They now have an "outperform" rating on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $6.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Leerink Partners from $7.00 to $9.00. They now have an "outperform" rating on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) was given a new $18.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Ratings data for XERS provided by MarketBeat
Neueste Beiträge
ykapse12 in Discuss Super Micro Computer, Super Micro Computer Inc.